Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsNASALStandard

XHANCE

FLUTICASONE PROPIONATE

Standard Dose
0.093MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview XHANCE is listed in Drugs@FDA under application 209022 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient FLUTICASONE PROPIONATE Form and strength SPRAY, METERED;NASAL - 0.093MG Sponsor PARATEK PHARMS Submission history Latest submission status date: 2024-03-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview XHANCE is listed in Drugs@FDA under application 209022 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient FLUTICASONE PROPIONATE Form and strength SPRAY, METERED;NASAL - 0.093MG Sponsor PARATEK PHARMS Submission history Latest submission status date: 2024-03-15 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.